Industry Insights

On a Panel at Pharma Tech Summit 2026, we discussed multiple perspectives around AI usage in biotech. Here's what we learned.

Lee Smith and Oyeronke Oyebanji sat down with BioProcess Insider to discuss the vaccine development and delivery practices in Nigeria: the good, the bad, and the path forward.

We reflect on our time at the BIO International Convention in the US from 2025, providing insights in how the event works, what we liked, and how you can get the most out of it for your needs.

Commercial strategy is always considered too late. Without having an end image in mind, it creates problems across operations during the development process, not the least being investors don't know what they're investing in.

Animal models have long underpinned vaccine development by enabling preclinical evaluation of immunogenicity, efficacy, safety, and dose selection, and they remain integral to regulatory submissions and certain approval pathways such as the FDA Animal Rule.

The COVID-19 pandemic transformed vaccine development by compressing timelines from decades to months, proving that rapid innovation is possible through parallel development, adaptive regulation, and unprecedented global equity.

AI is advancing faster than biotech's frameworks were designed to support. In a recent Bioprocess Online column, our Managing Partners Lee and Andrew have documented what they think it will take for biotech to effectively integrate AI at the pace innovation now takes place.

GreyRigge Associates partner with Pharma and Biotech consultancy: SciPot Consultancy